医械巨头Danaher(DHR.US)斥资57亿美元全现金收购英国生命科学用品制造商Abcam(ABCM.US)

智通财经网2023-08-29

全球规模最大的医疗工具供应商之一Danaher Corp(DHR.US)周一同意以57亿美元全现金(含债务)收购英国生命科学用品制造商Abcam(ABCM.US)，以扩大其产品和服务组合。此次收购交易已得到Abcam董事会和Danaher董事会的一致批准。交易预计将于2024年年中完成。资料显示，Abcam为全球三分之二的生命科学家提供超11万种蛋白质靶点研究产品，包括抗体、蛋白质、裂解液、生化...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2363487020?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2023-08-29 11:28","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2363487020","market":"hk","top_or_hot":-1,"title":"医械巨头Danaher(DHR.US)斥资57亿美元全现金收购英国生命科学用品制造商Abcam(ABCM.US)","media":"智通财经网","content":"<div>\n<p>全球规模最大的医疗工具供应商之一Danaher Corp(DHR.US)周一同意以57亿美元全现金(含债务)收购英国生命科学用品制造商Abcam(ABCM.US)，以扩大其产品和服务组合。此次收购交易已得到Abcam董事会和Danaher董事会的一致批准。交易预计将于2024年年中完成。资料显示，Abcam为全球三分之二的生命科学家提供超11万种蛋白质靶点研究产品，包括抗体、蛋白质、裂解液、生化...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/hkstock/ggscyd/2023-08-29/doc-imzivtsf9240626.shtml\">网页链接</a>\n\n</div>\n","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>医械巨头Danaher(DHR.US)斥资57亿美元全现金收购英国生命科学用品制造商Abcam(ABCM.US)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n医械巨头Danaher(DHR.US)斥资57亿美元全现金收购英国生命科学用品制造商Abcam(ABCM.US)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-08-29 11:28 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/hkstock/ggscyd/2023-08-29/doc-imzivtsf9240626.shtml><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>全球规模最大的医疗工具供应商之一Danaher Corp(DHR.US)周一同意以57亿美元全现金(含债务)收购英国生命科学用品制造商Abcam(ABCM.US)，以扩大其产品和服务组合。此次收购交易已得到Abcam董事会和Danaher董事会的一致批准。交易预计将于2024年年中完成。资料显示，Abcam为全球三分之二的生命科学家提供超11万种蛋白质靶点研究产品，包括抗体、蛋白质、裂解液、生化...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/hkstock/ggscyd/2023-08-29/doc-imzivtsf9240626.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2125910336.SGD","symbol_name":"Natixis Thematics Water R/A SGD","start_time":0,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2023-08-29/doc-imzivtsf9240626.shtml","article_id":"2363487020","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2363487020","pubTimestamp":1693279680,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"全球规模最大的医疗工具供应商之一Danaher Corp周一同意以57亿美元全现金(含债务)收购英国生命科学用品制造商Abcam，以扩大其产品和服务组合。此次收购交易已得到Abcam董事会和Danaher董事会的一致批准。据悉，收购完成后，Abcam有望作为Danaher生命科学部门的独立运营公司和品牌，进一步推进Danaher的战略，帮助绘制复杂疾病图谱，加速药物发现过程。分析师表示，Abcam的业务对Danaher来说是一项利润率更高的业务。Danaher在2021年以96亿美元收购了生物技术公司Aldevron。","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2125910336.SGD":"Natixis Thematics Water R/A SGD","LU0175139822.USD":"AB FCP I Global Equity Blend A USD","LU1923621640.USD":"Natixis Thematics Water R/A USD","LU0511384066.AUD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (AUDHDG) ACC","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","LU0882574055.USD":"富达全球健康医疗A ACC","BK4504":"桥水持仓","BK4581":"高盛持仓","LU0289960550.SGD":"AB FCP I - GLOBAL EQUITY BLEND PORTFOLIO 'A' (SGD) ACC","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","LU0122379950.USD":"贝莱德世界健康科学A2","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","ABCM":"Abcam plc","LU2125909593.SGD":"Natixis Thematics Meta R/A SGD","LU0289739343.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (SGD) ACC","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0528227936.USD":"富达环球人口趋势基金A-ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU1917777945.USD":"安联专题基金Cl AT Acc","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU2125909247.SGD":"Natixis Thematics Meta H-R/A SGD","BK4534":"瑞士信贷持仓","LU1923622614.USD":"Natixis Thematics Meta R/A USD","DHR":"丹纳赫","BK4585":"ETF&股票定投概念","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","LU0109391861.USD":"富兰克林美国机遇基金A Acc","BK4139":"生物科技","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0289961442.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"AX\" (SGD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","SG9999001176.USD":"United Global Healthcare Acc USD","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","LU0312595415.SGD":"Schroder ISF Global Climate Change Equity A Acc SGD","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","LU0390134368.USD":"FRANKLIN GLOBAL GROWTH \"A\" (USD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","BK4121":"生命科学工具和服务","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","BK4588":"碎股","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","LU2125910179.SGD":"Natixis Thematics Water H-R/A SGD","LU2063271972.USD":"富兰克林创新领域基金","LU0097036916.USD":"贝莱德美国增长A2 USD"},"translate_title":"Medical equipment giant Danaher (DHR.US) spent 5.7 billion US dollars on Abcam (ABCM.US), a British life science products manufacturer in All-cash deal","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABCM":1,"DHR":1},"content_text":"全球规模最大的医疗工具供应商之一Danaher Corp(DHR.US)周一同意以57亿美元全现金(含债务)收购英国生命科学用品制造商Abcam(ABCM.US)，以扩大其产品和服务组合。此次收购交易已得到Abcam董事会和Danaher董事会的一致批准。交易预计将于2024年年中完成。资料显示，Abcam为全球三分之二的生命科学家提供超11万种蛋白质靶点研究产品，包括抗体、蛋白质、裂解液、生化试剂、试剂盒和检测，以推进药物发现、生命科学研究和诊断。据悉，收购完成后，Abcam有望作为Danaher生命科学部门的独立运营公司和品牌，进一步推进Danaher的战略，帮助绘制复杂疾病图谱，加速药物发现过程。对于Danaher来说，这笔交易将帮助该公司缓解一些面临融资危机的规模较小的生物技术公司对其部分产品需求带来的冲击。Evercore ISI分析师Vijay Kumar表示：“这对Danaher来说是一笔不错的交易。”分析师表示，Abcam的业务对Danaher来说是一项利润率更高的业务。收购Abcam是Danaher为扩大影响力而进行的一系列交易中的最新一笔。Danaher在2021年以96亿美元收购了生物技术公司Aldevron。在此之前，Danaher在2019年以214亿美元收购了通用电气(GE.US)的生物制药解决方案业务。\n\n现在送您60元福利红包，直接提现不套路~~~快来参与活动吧！\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2363487020"}